Apellis Pharmaceuticals (NASDAQ:APLS) Given New $57.00 Price Target at Wedbush

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective lowered by Wedbush from $67.00 to $57.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2025 earnings at $2.23 EPS.

A number of other research firms also recently issued reports on APLS. Oppenheimer increased their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an outperform rating in a research report on Tuesday, January 30th. HC Wainwright reissued a buy rating and set a $92.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday. Mizuho reissued a neutral rating and set a $60.00 price target on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Raymond James raised their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a strong-buy rating in a research report on Thursday, January 11th. Finally, Jefferies Financial Group raised Apellis Pharmaceuticals from a hold rating to a buy rating and raised their price objective for the company from $68.00 to $80.00 in a research report on Monday, February 5th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $77.93.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $48.03 on Wednesday. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $60.54 and its two-hundred day simple moving average is $57.04. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The firm has a market cap of $5.79 billion, a price-to-earnings ratio of -10.72 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. During the same quarter in the prior year, the company earned ($1.50) EPS. The business’s revenue was up 545.9% compared to the same quarter last year. Analysts predict that Apellis Pharmaceuticals will post -1.33 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, CAO James George Chopas sold 1,061 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $68,965.00. Following the completion of the transaction, the chief accounting officer now directly owns 39,067 shares in the company, valued at $2,539,355. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CAO James George Chopas sold 1,061 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $65.00, for a total value of $68,965.00. Following the completion of the transaction, the chief accounting officer now directly owns 39,067 shares in the company, valued at $2,539,355. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director A. Sinclair Dunlop sold 18,681 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the completion of the transaction, the director now owns 173,998 shares of the company’s stock, valued at $9,949,205.64. The disclosure for this sale can be found here. Insiders sold a total of 406,651 shares of company stock worth $25,130,257 over the last three months. 7.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Wynnefield Capital Inc. purchased a new position in Apellis Pharmaceuticals during the third quarter valued at approximately $380,000. General American Investors Co. Inc. acquired a new stake in Apellis Pharmaceuticals in the third quarter valued at approximately $1,712,000. Profund Advisors LLC grew its holdings in Apellis Pharmaceuticals by 114.5% in the third quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock valued at $1,337,000 after purchasing an additional 18,766 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Apellis Pharmaceuticals by 6.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock valued at $33,451,000 after purchasing an additional 50,835 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).